These results indicate β6-integrin might be a novel therapeutic target in colon cancer therapy, and it reminded us that if positive αvβ6 and Ets-1 were found in patients with colon cancer of early stage, compared with negative, we would take more aggressive chemotherapy, or more frequent reexamination. Here, ETS1 is linked to malignant colon neoplasm.